Consensus Statement on the Management of Patients With Asymptomatic Hyperuricemia in General Medical Practice
Authors:
- Oksana M. DrapkinaODOksana M. Drapkina
- Vadim I. MazurovVMVadim I. Mazurov
- Martynov I. MartynovMMMartynov I. Martynov
- Evgeny L. NasonovENEvgeny L. Nasonov
- Sergey A. SaiganovSSSergey A. Saiganov
- Aleksander M. LilaALAleksander M. Lila
- Roman A. BashkinovRBRoman A. Bashkinov
- Irina N. BobkovaIBIrina N. Bobkova
- Chokan T. BaimukhamedovCBChokan T. Baimukhamedov
- Inna Z. GaydukovaIGInna Z. Gaydukova
- Nadir I. HuseynovNHNadir I. Huseynov
- Dmitry V. DuplyakovDmitry V. Duplyakov
Open Access
- 13 May 2025
- journal article
- Published by ECO-Vector LLC in HERALD of North-Western State Medical University named after I.I. Mechnikov
- Vol. 17 (1) , 113-132
Abstract
Hyperuricemia is a condition characterized by an increase of serum uric acid level above 360 µmol/L. It is known that high serum uric acid levels are not only the condition for the etiopathogenesis of gout but also an important risk factor for the development and progression of cardiovascular diseases, kidney and liver pathologies, type 2 diabetes, and others. This makes hyperuricemia a relevant issue in general therapeutic practice. Despite extensive evidence on the negative role of hyperuricemia in many internal organ diseases, the management strategy for patients with asymptomatic hyperuricemia in real clinical practice remains a subject of debate. This resolution represents an interdisciplinary consensus of experts from Commonwealth of Independent States, based on current evidence-based medicine data and proprietary registries. The proposed algorithm emphasizes the importance of a personalized approach to the treatment of hyperuricemia, taking into account the severity of comorbid conditions and the level of cardiovascular risk. Step-by-step recommendations are provided for general practitioners, family doctors, and a wide range of specialists in both non-pharmacological and pharmacological urate-lowering therapy. These guidelines aim to improve the quality of medical care for patients at high risk of socially significant diseases occurring together with asymptomatic hyperuricemia.Keywords
This publication has 93 references indexed in Scilit:
- 2020 American College of Rheumatology Guideline for the Management of GoutArthritis Care & Research, 2020
- At the crossroads of gout and psoriatic arthritis: “psout”Clinical Rheumatology, 2020
- Coexistent Hyperuricemia and Gout in Rheumatoid Arthritis: Associations With Comorbidities, Disease Activity, and MortalityArthritis Care & Research, 2019
- Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007–2016Arthritis & Rheumatology, 2019
- New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety AlertArthritis & Rheumatology, 2018
- Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitus—a 4.6‐year cohort studyDiabetes/Metabolism Research and Reviews, 2015
- Serum Uric Acid Levels and Diabetic Peripheral Neuropathy in Type 2 Diabetes: a Systematic Review and Meta-analysisMolecular Neurobiology, 2015
- Uric Acid as a Predictor of In-Hospital Mortality in Acute Myocardial Infarction: A Meta-analysisCell Biochemistry and Biophysics, 2014
- Hyperuricemia and incident hypertension: A systematic review and meta‐analysisArthritis Care & Research, 2010
- Involvement of Macrophage Migration Inhibitory Factor (MIF) in Experimental Uric Acid NephropathyMolecular Medicine, 2000